Journal
DRUGS OF TODAY
Volume 57, Issue 8, Pages 483-490Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2021.57.8.3280599
Keywords
Atoltivimab; Maftivimab; Odesivimab; Inmazeb; Ebola virus disease; Monoclonal anti-bodies; Drugs targeting Zaire ebolavirus glycoprotein; Antiviral drugs; Combination therapy
Categories
Ask authors/readers for more resources
Zaire ebolavirus has caused catastrophic outbreaks with high mortality rates and Inmazeb is the first FDA-approved treatment for this infection, displaying significant efficacy in clinical trials.
Zaire ebolavirus has been responsible for several catastrophic outbreaks with a high mortality rate. Unfortunately, there were no approved therapies or vaccines to treat or prevent infections caused by Ebola virus (EBOV) or other filoviruses. Atoltivimab/maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved treatment for Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who is reverse transcription polymerase chain reaction (RT-PCR)-positive for Zaire ebolavirus infection. The efficacy of Inmazeb has been established in vivo and it has successfully completed a phase I clinical trial in healthy individuals with no drug-related adverse effects. Additionally, Inmazeb has displayed significant reduction in mortality in the PALM (PAmoja tuLinde Maisha) trial, when compared with the control arm receiving ZMapp. Inmazeb has received orphan drug designation from both the U.S. FDA and the European Medicines Agency (EMA).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available